Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 20/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.48 |
| ▸ | HTR1A | P08908 | 2/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.48 |
| ▸ | HTR2A | P28223 | 2/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.48 |
| ▸ | HTR2B | P41595 | 2/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13631034 | 0.88 | REN (0.52) | RENCYP3A4ADRA1AKCNH2HTR1A | |
| SCHEMBL13434395 | 0.88 | REN (0.52) | RENCYP3A4ADRA1AKCNH2HTR1A | |
| SCHEMBL13434615 | 0.88 | REN (0.52) | RENCYP3A4ADRA1AKCNH2HTR1A | |
| SCHEMBL13434579 | 0.88 | REN (0.63) | RENCYP3A4ADRA1AKCNH2HTR1A | |
| SCHEMBL13434616 | 0.88 | REN (0.63) | RENCYP3A4ADRA1AKCNH2HTR1A | |
| SCHEMBL13461280 | 0.88 | REN (0.63) | RENCYP3A4ADRA1AKCNH2HTR1A | |
| SCHEMBL13461306 | 0.88 | REN (0.51) | RENCYP3A4ADRA1AKCNH2HTR1A | |
| SCHEMBL13461269 | 0.88 | REN (0.53) | RENCYP3A4ADRA1AKCNH2HTR1A | |
| SCHEMBL13461334 | 0.86 | REN (0.49) | RENCYP3A4ADRA1AKCNH2HTR1A | |
| SCHEMBL13461450 | 0.85 | REN (0.47) | RENCYP3A4ADRA1AKCNH2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056497-A1 | AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056497-A1 | AMIDE DERIVATIVE | REN, AGTR1, AGTR2 | REN 1/4885CYP3A4 537/4885ADRA1A 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.